Accelerated Proof of Concept for MASH/NASH (12–16 weeks)
Translational in vivo efficacy integrating NRF2 pharmacodynamic biomarkers. Endpoints: NAS (steatosis, inflammation, ballooning), fibrosis, ALT/AST, lipids, hepatic NRF2 biomarkers. Animal models: STAM and choline-deficient variants (in collaboration with IIB “Sols-Morreale” CSIC-UAM). Imaging: MRI for non-invasive hepatic/adipose metabolism assessment.
*Contact us for details
Your Dynamic Snippet will be displayed here...
This message is displayed because youy did not provide both a filter and a template to use.